Skip to main content

Peer Review reports

From: Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study

Original Submission
1 Mar 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
9 Mar 2021 Reviewed Reviewer Report
13 Mar 2021 Reviewed Reviewer Report
23 Mar 2021 Author responded Author comments - Weiguang Yu
Resubmission - Version 3
23 Mar 2021 Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
25 Mar 2021 Author responded Author comments - Weiguang Yu
Resubmission - Version 5
25 Mar 2021 Submitted Manuscript version 5
26 Mar 2021 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
30 Mar 2021 Editorially accepted
13 Apr 2021 Article published 10.1186/s12885-021-08156-1

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us